echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Lizhu group vancomycin hydrochloride for injection has been approved for marketing!

    Lizhu group vancomycin hydrochloride for injection has been approved for marketing!

    • Last Update: 2019-12-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On December 24, Lizhu pharmaceutical factory, a wholly-owned subsidiary of Lizhu Pharmaceutical Group Co., Ltd., received the approval document for drug registration (approval No.: 2019s00681) approved and issued by the State Drug Administration Examination and approval conclusion: according to the drug administration law of the people's Republic of China and relevant regulations, after examination, this product meets the relevant requirements of drug registration, approves the registration and issues the drug approval number Vancomycin hydrochloride for injection is a product independently developed by the company, with indications as follows: 1 This product is suitable for the treatment of severe or fatal infection caused by vancomycin sensitive methicillin resistant Staphylococcus (β - lactam resistant); 2 This product is effective for the treatment of endocarditis caused by Staphylococcus; 3 It is effective to treat endocarditis caused by Streptococcus viridis or Streptococcus bovis with aminoglycosides alone or in combination; 4 It is effective to treat endocarditis caused by diphtheria like bacilli with vancomycin This product mainly plays a bactericidal role by inhibiting the biosynthesis of cell wall In addition, vancomycin can change the permeability of bacterial cell membrane and RNA synthesis, and there is no cross resistance between vancomycin and other antibiotics The acceptance time of the first production application submitted by the company is July 17, 2013 (acceptance No.: cyhs1301080 Yue) As of the date of this announcement, the cumulative direct investment in R & D of vancomycin hydrochloride for injection is about 6.9101 million yuan At present, the market situation of similar drugs in China includes vancomycin, teicoplanin and norvancomycin According to the database on the official website of the State Drug Administration, as of the date of this announcement, there are 6 domestic enterprises (including Lizhu pharmaceutical factory of Lizhu group) approved for listing vancomycin hydrochloride for injection Mengmeng's article is the integrated content of yaozhi.com, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.